Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 With or Without Pertuzumab in HER2-Positive Breast Cancer
NCT06057610Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab rezetecan in breast cancer (3 arms), sponsored by Hengrui. Primary endpoint: Progression Free Survival by Blinded Independent Central Review at 3 years. Started Nov 2023; status: active, not recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06057610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057610.